<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532749</url>
  </required_header>
  <id_info>
    <org_study_id>CR108805</org_study_id>
    <secondary_id>42847922MDD3002</secondary_id>
    <secondary_id>2020-000338-16</secondary_id>
    <nct_id>NCT04532749</nct_id>
  </id_info>
  <brief_title>A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as&#xD;
      adjunctive therapy to an antidepressant in improving depressive symptoms in participants with&#xD;
      major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response&#xD;
      to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or&#xD;
      serotonin-norepinephrine reuptake inhibitor (SNRI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant&#xD;
      (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R)&#xD;
      that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study&#xD;
      is that adjunctive treatment with seltorexant is superior to placebo in treating depressive&#xD;
      symptoms, as measured by change in Montgomery Asberg Depression Rating Scale (MADRS) total&#xD;
      score from baseline to Day 43 in adult and elderly participants with MDDIS who have had an&#xD;
      inadequate response to treatment with a SSRI/SNRI. The study will be conducted in 3 phases: a&#xD;
      screening phase (up to 30 days), a double-blind (DB) treatment phase (43 days), and a post&#xD;
      treatment follow-up phase (7 to 14 days after DB treatment phase). Total duration of study is&#xD;
      up to 12 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at&#xD;
      specified time points during this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">January 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 6, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 43</measure>
    <time_frame>Baseline to Day 43</time_frame>
    <description>MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score to Day 43</measure>
    <time_frame>Baseline to Day 43</time_frame>
    <description>MADRS-WOSI considered 9 of the 10 MADRS items, excluding &quot;reduced sleep&quot; item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a T-score to Day 43</measure>
    <time_frame>Baseline to Day 43</time_frame>
    <description>The PROMIS-Sleep Disturbance (PROMIS-SD) is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. A higher score on 5 of the 8 items reflects a worse outcome, whereas a higher score on 3 items reflects an improved outcome; therefore, the directionality of the 8 item scores are first synchronized prior to calculation of the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the MADRS-6 Total Score to Day 43</measure>
    <time_frame>Baseline to Day 43</time_frame>
    <description>The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale is a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: Apparent Sadness, Reported Sadness, Inner Tension, Lassitude, Inability to Feel, and Pessimistic Thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Response on Depressive Symptoms Scale Based on Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to Day 43</measure>
    <time_frame>Baseline to Day 43</time_frame>
    <description>Responders are defined as participants with greater than or equal to (&gt;=) 50 percent (%) improvement in the MADRS total score from baseline to Day 43.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score to Day 43</measure>
    <time_frame>Baseline to Day 43</time_frame>
    <description>The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Seltorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo tablets orally once daily from Day 1 to Day 42 (until the end of Week 6).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seltorexant</intervention_name>
    <description>Participants will receive Seltorexant tablets.</description>
    <arm_group_label>Seltorexant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo tablets.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5)&#xD;
             diagnostic criteria for major depressive disorder (MDD), without psychotic features,&#xD;
             based upon clinical assessment and confirmed by the structured clinical interview for&#xD;
             DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first&#xD;
             depressive episode prior to age 60. The duration of the current depressive episode&#xD;
             must be less than or equal to (&lt;=) 24 months&#xD;
&#xD;
          -  Have had an inadequate response to at least 1 but no more than 2 antidepressants,&#xD;
             administered at an adequate dose and duration in the current episode of depression.&#xD;
             The current antidepressant cannot be the first antidepressant treatment for the first&#xD;
             lifetime episode of depression. An inadequate response is defined as less than (&lt;) 50&#xD;
             percent (%) reduction but with some improvement (that is, improvement greater than [&gt;]&#xD;
             0%) in depressive symptom severity with residual symptoms other than insomnia present,&#xD;
             and overall good tolerability, as assessed by the MGH-ATRQ&#xD;
&#xD;
          -  Is receiving and tolerating well any one of the following selective serotonin reuptake&#xD;
             inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive&#xD;
             symptoms at screening, in any formulation and available in the participating country:&#xD;
             citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran,&#xD;
             levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or&#xD;
             vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks, and&#xD;
             for no greater than 18 months in the current episode&#xD;
&#xD;
          -  Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to&#xD;
             (&gt;=) 20 at the first screening interview, must not demonstrate a clinically&#xD;
             significant improvement (that is [ie], an improvement of &gt; 20 % on their HDRS-17 total&#xD;
             score) from the first to the second independent HDRS-17 rating, and must have a&#xD;
             HDRS-17 total score &gt;= 18 at the second screening interview&#xD;
&#xD;
          -  Have a patient version of the Insomnia Severity Index (ISI) total score &gt;=15 as well&#xD;
             as a clinician version of the ISI total score &gt;=15 at the second screening visit&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2) inclusive&#xD;
             (BMI=weight/height^2)&#xD;
&#xD;
          -  Participant must be medically stable on the basis of clinical laboratory tests&#xD;
             performed at screening&#xD;
&#xD;
          -  Participant must be medically stable on the basis of the following: physical&#xD;
             examination (including a brief neurological examination), vital signs (including blood&#xD;
             pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a recent (last 3 months) history of, or current signs and symptoms of, severe&#xD;
             renal insufficiency (creatinine clearance [CrCl] &lt; 30 milliliter per minute [mL/min]);&#xD;
             clinically significant or unstable cardiovascular, respiratory, gastrointestinal,&#xD;
             neurologic, hematologic, rheumatologic, immunologic or endocrine disorders and&#xD;
             uncontrolled Type 1 or Type 2 diabetes mellitus&#xD;
&#xD;
          -  Has clinically significant hepatic disease as defined by &gt;=2*Upper Limit of Normal&#xD;
             (ULN) increase of aspartate aminotransferase (AST) or alanine aminotransferase (ALT)&#xD;
             at screening&#xD;
&#xD;
          -  Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more&#xD;
             adequate antidepressant treatments in the current episode, as indicated by no or&#xD;
             minimal (&lt; 25% improvement in symptoms) when treated with an antidepressant of&#xD;
             adequate dose (per massachusetts general hospital-antidepressant treatment response&#xD;
             questionnaire [MGH-ATRQ]) and duration (at least 6 weeks).&#xD;
&#xD;
          -  Has history or current diagnosis of a psychotic disorder, bipolar disorder,&#xD;
             intellectual disability, autism spectrum disorder, borderline personality disorder, or&#xD;
             somatoform disorders&#xD;
&#xD;
          -  Has any significant primary sleep disorder, including but not limited to obstructive&#xD;
             sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia&#xD;
             disorder are allowed&#xD;
&#xD;
          -  Has a history of moderate to severe substance use disorder including alcohol use&#xD;
             disorder according to DSM-5 criteria within 6 months before screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialists, LLC</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Valley Research Center</name>
      <address>
        <city>Imperial</city>
        <state>California</state>
        <zip>92251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Excell Research Inc</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group, Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innova Clinical Trials</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harmony Clinical Research Inc</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Research Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Compass Research LLC-Bioclinica Research</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uptown Research Institute, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research, Inc.</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Michigan Clinical Research Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastside Comprehensive Medical Services</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Community Research Management Associates, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sites, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intend Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research, LLC</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Privada Banfield S.A</name>
      <address>
        <city>Banfield</city>
        <zip>B1828CKR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>STAT Research S.A.</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1013AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NOVAIN Neurociencias Group</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C10154ABQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación para el Estudio y Tratamiento de las Enfermedades Mentales</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1425AHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CEN-Consultorios Especializados en Neurociencias</name>
      <address>
        <city>Cordoba</city>
        <zip>5000FJF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Médico DAMIC</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanatorio Prof. Leon S. Morra</name>
      <address>
        <city>Cordoba</city>
        <zip>X5009BIN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>INSA Instituto de Neurociencias San Agustín</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>C.I.A.P. (Centro de investigación y Asistencia en Psiquiatría)</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Mayo de UMCB</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IHE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psicomed Estudios Medicos</name>
      <address>
        <city>Antofagasta</city>
        <zip>1270244</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioMedica Research Group</name>
      <address>
        <city>Santiago</city>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CeCim - Centro de Estudios Clinicos e Investigacion Medica</name>
      <address>
        <city>Santiago</city>
        <zip>8320000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Hernan Henriquez Aravena</name>
      <address>
        <city>Temuco</city>
        <zip>47811-51</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psykiatriskt Center Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Psykiatrisk Center Nordsjaelland</name>
      <address>
        <city>Hillerod</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psykiatriskt Center Kopenhavn</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ålborg Universitetshospital</name>
      <address>
        <city>Ålborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eira Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>150</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mederon LTD at ARTES</name>
      <address>
        <city>Helsinki</city>
        <zip>270</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Savon Psykiatripalvelu</name>
      <address>
        <city>Kuopio</city>
        <zip>70110</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oulu Mentalcare Oy</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Satakunnan Psykiatripalvelu</name>
      <address>
        <city>Rauma</city>
        <zip>26100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan-si</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>1830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunway Medical Centre</name>
      <address>
        <city>Bandar Sunway</city>
        <zip>47500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Jalan Pahang</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sibu</name>
      <address>
        <city>Sibu</city>
        <zip>96001</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Podlaskie Centrum Psychogeriatrii</name>
      <address>
        <city>Bialystok</city>
        <zip>15-756</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddzial w Czestochowie</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddzial w Katowicach</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS</name>
      <address>
        <city>Leszno</city>
        <zip>64-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <zip>90-127</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Luxmed Sp z o o</name>
      <address>
        <city>Lublin</city>
        <zip>20-109</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatricka Ambulancia Mentum S.R.O.</name>
      <address>
        <city>Bratislava</city>
        <zip>82007</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatricka Ambulancia Centrum Zdravia R.B.K. S.R.O.</name>
      <address>
        <city>Svidník</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Crystal Comfort s.r.o.</name>
      <address>
        <city>Vranov nad Toplou</city>
        <zip>9301</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BONA MEDIC, s.r.o.</name>
      <address>
        <city>Zlate Moravce</city>
        <zip>95301</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council</name>
      <address>
        <city>Kherson,Vil. Stepanivka</city>
        <zip>73488</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cnce 'Kyiv City Psychoneurological Hospital #2' of Executive Body of Kyiv City Council (Kcsa)</name>
      <address>
        <city>Kyiv</city>
        <zip>02192</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Main Military Clinical Hospital of MDU</name>
      <address>
        <city>Kyiv</city>
        <zip>1133</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyiv Clinical Railway Hospital #2 of the Branch Health Care Center of the PJSC Ukrainian Railway</name>
      <address>
        <city>Kyiv</city>
        <zip>3049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital'</name>
      <address>
        <city>Lviv</city>
        <zip>79021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CI Odesa Regional Medical Center of Mental Health</name>
      <address>
        <city>Odesa</city>
        <zip>65014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNCE Odesa regional psychiatric hospital #2 Odesa regional council</name>
      <address>
        <city>Oleksandrivka</city>
        <zip>67513</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poltava O.F. Maltsev RC Psychiatric Hospital Dept #9 (Ad-P Dept) HSEIU Ukrainian MSA</name>
      <address>
        <city>Poltava</city>
        <zip>36006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council'</name>
      <address>
        <city>Smila</city>
        <zip>20708</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CI O.I. Yuschenko VRPsH Depts #7 &amp; #10 M.I. Pyrogov VNMU</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108805</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

